J. B. Chemicals & Pharmaceuticals Bilanço Sağlığı
Finansal Sağlık kriter kontrolleri 5/6
J. B. Chemicals & Pharmaceuticals şirketinin toplam hissedar öz sermayesi ₹29.2B ve toplam borcu ₹3.8B olup, bu da borç-öz sermaye oranını 12.9% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla ₹39.9B ve ₹10.7B dir. J. B. Chemicals & Pharmaceuticals 'in FAVÖK'ü ₹7.9B faiz karşılama oranı 24.2 dur. Şirketin ₹4.6B tutarında nakit ve kısa vadeli yatırımları bulunmaktadır.
Anahtar bilgiler
12.9%
Borç/özkaynak oranı
₹3.78b
Borç
| Faiz karşılama oranı | 24.2x |
| Nakit | ₹4.60b |
| Eşitlik | ₹29.23b |
| Toplam yükümlülükler | ₹10.71b |
| Toplam varlıklar | ₹39.94b |
Son finansal sağlık güncellemeleri
These 4 Measures Indicate That J. B. Chemicals & Pharmaceuticals (NSE:JBCHEPHARM) Is Using Debt Reasonably Well
Jun 28
We Think J. B. Chemicals & Pharmaceuticals (NSE:JBCHEPHARM) Can Stay On Top Of Its Debt
Nov 29Is J. B. Chemicals & Pharmaceuticals (NSE:JBCHEPHARM) Using Too Much Debt?
Dec 03J. B. Chemicals & Pharmaceuticals (NSE:JBCHEPHARM) Seems To Use Debt Quite Sensibly
Aug 03Does J. B. Chemicals & Pharmaceuticals (NSE:JBCHEPHARM) Have A Healthy Balance Sheet?
Mar 29Recent updates
J. B. Chemicals & Pharmaceuticals Limited's (NSE:JBCHEPHARM) Business Is Yet to Catch Up With Its Share Price
Sep 24Most Shareholders Will Probably Agree With J. B. Chemicals & Pharmaceuticals Limited's (NSE:JBCHEPHARM) CEO Compensation
Aug 15J. B. Chemicals & Pharmaceuticals Limited Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Aug 11These 4 Measures Indicate That J. B. Chemicals & Pharmaceuticals (NSE:JBCHEPHARM) Is Using Debt Reasonably Well
Jun 28J. B. Chemicals & Pharmaceuticals Limited (NSE:JBCHEPHARM) Not Flying Under The Radar
Apr 19J. B. Chemicals & Pharmaceuticals Limited Just Missed Earnings - But Analysts Have Updated Their Models
Feb 09J. B. Chemicals & Pharmaceuticals Limited (NSE:JBCHEPHARM) Not Flying Under The Radar
Dec 22We Think J. B. Chemicals & Pharmaceuticals (NSE:JBCHEPHARM) Can Stay On Top Of Its Debt
Nov 29J. B. Chemicals & Pharmaceuticals' (NSE:JBCHEPHARM) Dividend Will Be Increased To ₹9.25
Aug 03J. B. Chemicals & Pharmaceuticals (NSE:JBCHEPHARM) Is Due To Pay A Dividend Of ₹8.50
Feb 11Is J. B. Chemicals & Pharmaceuticals (NSE:JBCHEPHARM) Using Too Much Debt?
Dec 03A Look At The Intrinsic Value Of J. B. Chemicals & Pharmaceuticals Limited (NSE:JBCHEPHARM)
Sep 21J. B. Chemicals & Pharmaceuticals (NSE:JBCHEPHARM) Seems To Use Debt Quite Sensibly
Aug 03Estimating The Fair Value Of J. B. Chemicals & Pharmaceuticals Limited (NSE:JBCHEPHARM)
Jun 15Does J. B. Chemicals & Pharmaceuticals (NSE:JBCHEPHARM) Have A Healthy Balance Sheet?
Mar 29J. B. Chemicals & Pharmaceuticals (NSE:JBCHEPHARM) Has Re-Affirmed Its Dividend Of ₹8.50
Feb 16With EPS Growth And More, J. B. Chemicals & Pharmaceuticals (NSE:JBCHEPHARM) Is Interesting
Jan 27Finansal Durum Analizi
Kısa Vadeli Yükümlülükler: JBCHEPHARM 'nin kısa vadeli varlıkları ( ₹18.5B ) kısa vadeli yükümlülüklerini ( ₹8.7B ) aşıyor.
Uzun Vadeli Yükümlülükler: JBCHEPHARM şirketinin kısa vadeli varlıkları ( ₹18.5B ) uzun vadeli yükümlülüklerini ( ₹2.0B ) aşmaktadır.
Borç-Özkaynak Tarihçesi ve Analizi
Borç Seviyesi: JBCHEPHARM şirketinin toplam borcundan daha fazla nakiti var.
Borcun Azaltılması: JBCHEPHARM şirketinin borç/öz sermaye oranı son 5 yılda 1.7% seviyesinden 12.9% seviyesine yükseldi.
Borç Kapsamı: JBCHEPHARM 'nin borcu işletme nakit akışı ( 208.9% ) tarafından iyi bir şekilde karşılanmaktadır.
Faiz Kapsamı: JBCHEPHARM 'in borcuna ilişkin faiz ödemeleri EBIT ( 24.2 x kapsam) tarafından iyi bir şekilde karşılanmaktadır.